medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 2

<< Back Next >>

Gac Med Mex 2003; 139 (2)

Developments in Multiple Myeloma

I. Introduction.
II. Molecular Biology in Multiple Myeloma.
III. Novel Therapeutic Options for Multiple Myeloma.
IV. Prognostic Factors of Value in Multiple Myeloma.

Romero-García F, Vela-Ojeda J, Gutiérrez-Romero M, Delgado-Lamas JL

Language: Spanish
References: 52
Page: 131-138
PDF size: 78.34 Kb.


Text Extraction

No abstract


REFERENCES

  1. Pope B. Brown R, Luo XF, et al. Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumor suppressor genes and can be monitored by the oncoprotein phenotype. Leuk Lymphoma 1997;25:545-554.

  2. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of translocation t(11 ;14)(q13 ;q32) and t(4 ;14)(p16 ;q32) in patients with plasma cell malignancies. Cancer Res 1999;58:5640-5645.

  3. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;773-776.

  4. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 1997;275:1132-1136.

  5. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996;13:1511-1519.

  6. Puthier D, Pellat-Deceunynck C, Barille S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;12:289-294.

  7. Schwarze MMK, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6-mediated up-regulation of bcl-xl. Cancer Res 1995;55:2262-2265.

  8. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3 ;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 1997;16:260-264.

  9. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-1349.

  10. Winston JT, Coats SR, Wang YZ, Pledger W. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 1996;12:127-134.

  11. Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations : analysis of the Eastern Cooperative Oncology Group phase III trial. Blood 1996;88:2699-2706.

  12. Neri A, Baldini L, Tercca D, et al. P53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993;81:128-135.

  13. Rao PH, Cigudosa JC, Ning Y, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 1999;92:1743-1748.

  14. Ho IC, Hodge MR, Rooney JW, Glimcher LH. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996;88:973-983.

  15. Anderson KC. ASCO Educational book, 38th Meeting Orlando, Fla. May 2002. pp 479.

  16. Dhodapkar KM, et al. J Exp Med, 2002; 195:125-133.

  17. Martinelli G, et al. J Clin Oncology 2000; 18:2273-2281.

  18. Carbone PP, Kellerhouse LE Gehan EA. Plasmacytic myeloma: A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am. J Med. 1967;42:937-948.

  19. J. Bladé. Mieloma Múltiple Capítulo 31., Hematología Clínica Editor: J. Sans Sabrafen. 4ta. Edición Ediciones Harcourt. Madrid España 2001. pp:574-588.

  20. Durie BGM, Salmon SE. A clinical Staging system for multiple myeloma: correlation of measured cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-854.

  21. Boccadoro M., Pileri A. Standard chemotherapy for myelomatosis An Area of great controversy. Hematol /Oncol. Clin. North Amer. 1992,6:371-382.

  22. Sawyer JR, Schuster J., Nowotny H. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82:41-49.

  23. Facon T, Avet Loiseau H, Guillerm G. Chromosome 13 abnormalities identified by FISH and serum beta-2 microglobulin produce a powerful myeloma staging system. Blood 2001;97:1566-1571.

  24. Desikan R, Barlogie B, Sawyer J. Results of high dose therapy for 1000 patients with multiple myeloma durable complete remission and superior survival in the abscence of chromosome 13 abnormalities. Blood 2000;95:4008-4010.

  25. Bergsagel PL, Kuehl WM. Molecular Pathogenesis of Multiple Myeloma. Education Book American Soc. Hematology 2001. pp:157-177.

  26. Badros A, Barlogie B, Siegel E. Results of autologous stem cell transplant in MM patients with renal failure. Br. J. Haematol 2001;114:822-829.

  27. Bladé J, López-Guillermo A, Bosch F. Impact of response to treatment on survival in multiple myeloma: results in a serie of 243 patients. Br. J. Haematol. 1994;88:117-121.

  28. Myeloma Trialist Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J. Clin. Oncol 1998;16:3822-3842.

  29. Attal M, Harrosseau JL, Stoppa AM. A prospective randomized trial of autologous bone marrow transplant and chemotherapy in Multiple Myeloma. New Engl J. Med.1996;335:91-97.

  30. Fernand JP, Ravaud P, Katsahian M. High dose therapy and autologous blood stem cell transplant versus conventional treatment in Multiple myeloma, results of a randomized trial in 190 patients, 55 to 65 years of age. Blood 1999;94:396a.

  31. Tricot G, Sawyer JR, Jagannath S. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotrasplant. J. Clin. Oncol 1997;15:2659-2666.

  32. Tricot G, Spencer T, Sawyer JR. Predicting long term event free survival in multiple myeloma patients following planned tandem autotransplants. Brit. J. Haematol 2002;116:211-217.

  33. Vesole DH, Tricot G, Jagannath S. Autotrasplants in multiple myeloma : What have we learned ? Blood 1996:88:838-847.

  34. Vesole DH, Berlogie B, Jagannath S. High dose therapy for refractory multiple myeloma : improved prognosis with better supportive care and double trasnplants. Blood 1994;84:950-956.

  35. Moreau P, Milped N, Mahe B. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999;23:1003.1006.

  36. Bjorkstrand B, Goldstone AH, Ljungman P. Prognostic factors in autologous stem cell transplantation for multiple myeloma EBMT Registry European Group for Bone Marrow Transplantation. Leuk & Lymphoma 1994;15:265-272.

  37. Dumontet C, Ketterer N, Espinouse D. Reduced progression free survival in elderly patients receiving intensification with ABMT for multiple myeloma. Bone Marrow Transplant. 1998;21:1037-1041.

  38. Gertz MA, Lacy MQ, Inwards DJ. Delayed stem cell transplantation for the management of relapsed or refractory multiple mnyeloma. Bone Marrow Transplant. 2000;26:45-50.

  39. Jagannath S, Barlogie B, Dicke K. Autologous bone marrow transplantation in multiple myeloma: Identification of prognostic factors. Blood 1990;84:844-852.

  40. Rajkumar SV, Fonseca R, Lacy MQ. Plasmablastic morphology is an independent predictor of poor survival after autologous stem cell transplantation for myeloma. J Clin Oncol. 1999;17:1551-1557.

  41. Sirohi B, Powles R., Kulkarni S. Comparison of new patients with Bence Jones, IgG and Ig A myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant. 2001:28:29-37.

  42. Rajkumar SV, Fonseca R, Lacy MQ. Beta 2 microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999;23:1261-1266.

  43. Majolino I, Vignetti M, Meloni G. Autologous transplantation in multiple myeloma a GITMO retrospective analysis on 290 patients. Haematologica 1999;84:844-852.

  44. Rajkumar SV, Fonseca R, Lacy MQ. Abnormal cytogenetics predict poor survival alter high dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1999;24:497-503.

  45. La huerta JJ, Martinez López J, de la Serna J. Remission status defined by immunofixation versus electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br. J Haematol. 2000;109:438-446.

  46. Rajkumar SV, Fonseca R, Dewald GW. Cytogenetic abnormalities correlates with the plasma cell labelling index and extent of bone marrow involvement in myeloma. Cancer Genet. Cytogenet. 1999;113:73-77.

  47. Tricot G, Jagannath S, Vesole D. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-596.

  48. Barlogie B. High dose therapy and innovative approaches to treatment of multple myeloma. Semin. Hematol. 2001;38:21-27.

  49. Habn T, Wingard JR, Anderson CK, Bensinger WI, Berenson JR, Brozeit G, Carver JR, Kyle AR, McCarthy PL. The role of cytotoxic therapy with hematopoieic stem cell transplantation in the therapy of Multiple myeloma. An evidence based review. Biol. Blood & Bone Marrow Transpl. 2003;9:4-37.

  50. Weber D, Rankin K, Gavino M, Delasalle K Alexanian R. Thalidomide alone or with dexametasone for previously untreated Multiple Myeloma J.Clin. Oncol. 2003;21:16-19.

  51. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of Allogeneic Transplantation in High risk multiple myeloma patients after nonmyeloblative conditioning. J. Clin. Oncol. 2002;20:1295-1303.

  52. Rajmukar SV, Hayman S, Gertz MA, Dispenzieri A., Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle R, Witzig TE. Combination Therapy with Thalidomide plus Dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 2002;20:4319-4323.




2020     |     www.medigraphic.com